

EXECUTIVE SECRETARY REPORT – JUNE, 2018

- **FINANCIAL REPORT**

- 2018-2019 Budget

- **TEMPORARY LICENSES**

- **STAFF ACTIVITIES**

- Sunset Committee (4/23) – Brett, Dave
- Meetings with other health care boards – Dave, Paul, Brett
- Governor’s Task Force on Opiates (4/18) – Dave, Paul
- NABP Annual Meeting (May) - staff
- AB 474 meetings and continuing education - staff
- CORA meeting (4/26) - Yen

- **REPORT TO BOARD**

- BD product information

- **BOARD RELATED NEWS**

- **ACTIVITIES REPORT**

Regulation Tracking Log

Regulation Number and Topic	Workshop Propose To Bd	30 Days To LCB W/Letter	LCB R0 Number Issued	LCB Return Date	30 Days Post Public Hearing	Public Hearing Meeting Date	To LCB Final W/ Cov./Info	Secretary of State File Date	
639.955 Penalty for failing to transmit information required by NAC 639.926	03/02/16	03/11/16	R036-16	04/08/16	04/27/16	06/01/16	06/16/16	06/28/16	
639.921 Sharing information between systems.	03/02/16	03/11/16	R035-16	04/08/16	06/15/16	07/20/16	Denied 07/21/16		
453.NEW Naloxone	01/13/16	04/07/16	R058-16	05/04/16	06/15/16	07/20/16	08/05/16	09/09/16	
639.7102 Use of computer system for issuance and transmission of prescription	07/21/16 09/08/16 10/13/16	10/25/16	R154-16	07/05/17	08/02/17	09/07/17	09/27/17	10/31/17	
639.7105 Electronic transmission of prescription									
NAC 453.510 Schedule I add MAB-CHMINACA, AB-FUBINACA and ADB-PINACA	09/08/16	09/20/16	R151-16	Withdrawn – Duplicates R080-15					
453.540 Schedule IV add Eluxadoline	09/08/16	09/20/16	R150-16						
453.550 Schedule V add Brivaracetam	09/08/16	09/20/16	R149-16						
453.NEW Naloxone recordkeeping	10/13/16	10/25/16	R157-16	06/15/17	08/02/17	09/07/17	09/27/17	10/31/17	
453.460 Partial Filing of Prescriptions	03/01/17 10/19/17	03/21/17	R007-17	06/22/17	08/02/17	09/07/17 01/11/18	01/30/18	02/27/18	
	10/31/17: LCB drafting changes from 10/19/17 WS								
453.510 Schedule I adding certain controlled substances	04/13/17	05/03/17	R011-17	06/29/17	08/02/17	09/07/17	09/27/17	10/31/17	
453.530 Schedule III HCG in non-humans	06/01/17	06/07/17	R013-17	06/14/17	08/02/17	09/07/17	09/27/17	10/31/17	
453.440 DEA/CD-10 Requirements	07/20/17	07/28/17	R046-17	09/05/17	11/01/17	12/06/17	12/13/17	02/27/18	
639.926 Days Supply/Schedule V Reporting	07/20/17	07/28/17	R045-17	09/05/17	11/01/17	12/06/17	12/13/17	02/27/18	
639 Veterinarians dispensing through consignment	09/07/17 10/19/17	12/12/17	R146-17	02/01/18	02/01/18	03/07/18	04/05/18		

Regulation Tracking Log

Regulation Number and Topic	Workshop Propose To Bd	30 Days To LCB W/Letter	LCB R0 Number Issued	LCB Return Date	30 Days Post Public Hearing	Public Hearing Meeting Date	To LCB Final W/ Cov./Info	Secretary of State File Date
639.010 Definition of Designated Agent	12/06/17							
639.670 USP 800	10/19/17							
639.879 APRN Dispensing	10/19/17	Close – Adopting USP 800	R132-17	12/01/17				
639 NEW Prescription Readers	10/19/17	11/02/17	R131-17	12/05/17	01/24/18	03/07/18	03/28/18	
639 PMP Registration/Access	01/11/18	01/12/18	R013-18	04/30/18	03/13/18	04/12/18		
639 Show Cause	01/11/18	01/12/18	R014-18	02/27/18	05/03/18	06/07/18		
639.742 Vet Dispensing	01/11/18	01/12/18	R015-18	03/09/18	05/03/18	06/07/18		
639.220 Schedule of Fees	03/07/18	03/13/18	R047-18	04/17/18	03/13/18	04/12/18		
639.NEW Dispensing of CS in conformance with AB 474	03/07/18	03/15/18	R048-18	05/04/18	05/08/18	06/07/18		
453.510 Schedule I – Adding New Substances (Fentanyl)	03/07/18							

TEMPORARY LICENSES
(Issued since last board meeting)

Pipeline

Jamie Beever

Mesa View Regional Hospital

David Burchett

Renown

Mikayla Rageth

Walgreens

Payvand Hadjian



BD Diabetes Care
1 Becton Drive
Franklin Lakes, NJ
07417
bd.com

Important Product Information

BD Insulin Syringes

April 2018

For the Attention of:

Compounders, including 503B Outsourcing Facilities and Pharmacies
American Academy of Ophthalmology, American Society of Retina Specialists

Description of the problem and health hazard:

BD has become aware that its insulin syringes are being used for intraocular injections. Adverse events associated with "floaters" have been reported when insulin syringes are used for intraocular injections.

BD insulin syringes are intended for subcutaneous injection of insulin and have only been tested and validated for this intended use. These insulin syringes are safe and effective when used as intended.

Contact Information

If you have questions please contact us at 1-800 BD Cares (800-232-2737) between 8 AM and 5 PM ET Monday through Friday.

Please complete the attached acknowledgement form to confirm your receipt of this communication.

BD has informed the U.S. Food and Drug Administration of this safety alert. Any adverse health consequences experienced may be reported to the FDA's MedWatch Adverse Event Reporting program.

- Web: MedWatch website at www.fda.gov/medwatch
- Phone: 1-800-FDA-1088 (1-800-332-1088)
- Mail: MedWatch, HF-2, FDA, 5600 Fisher's Lane, Rockville, MD 20852-9787

BD is committed to advancing the world of health. Our primary objectives are patient and user safety. We thank you in advance for helping us to assure patient safety by using the insulin syringes only for their intended use.

Sincerely,

Laurence J. Hirsch, MD
VP Global Medical Affairs
BD Medical – Diabetes Care

Gail Griffiths
Sr. Director Regulatory Compliance
BD – US Region



Nevada State Board of Pharmacy

431 W. PLUMB LANE • RENO, NEVADA 89509
(775) 850-1440 • 1-800-364-2081 • FAX (775) 850-1444
E-mail: pharmacy@pharmacy.nv.gov • Website: bop.nv.gov

NEVADA STATE BOARD OF PHARMACY

ACTIVITIES REPORT

APRIL 11-12, 2018 BOARD MEETING HELD IN LAS VEGAS, NEVADA

This report is prepared and presented to keep interested legislators and others abreast of the activities of the Nevada State Board of Pharmacy. Following is a summary of the April 2018 Board meeting.

Licensing Activity:

- 6 licenses were granted for Out-of-State MDEG (Medical Devices, Equipment and Gases) companies and 1 granted for a Nevada MDEG company.
- 14 licenses were granted for Out-of-State pharmacies; pending receipt of a favorable inspection for all compounding pharmacies, and 1 license application for further information.
- 8 licenses were granted for Out-of-State wholesalers.
- 8 licenses were granted for Nevada pharmacies and 1 application pulled for further information
- 2 licenses were granted for Out-of-State Outsourcing Facilities & 1 application was postponed.
- 3 licenses were renewed and 1 denied for pharmacists with disciplinary issues in other states.
- 1 license was denied for a pharmacy tech in training for testing positive for a schedule 1 substance.
- A progress report was offered by a revoked pharmacist, who was asked to continue with his internship prior to reapplying for his license reinstatement.
- 1 license was granted for a Physician's Assistant with past regulatory issues.

Disciplinary Actions:

- Pharmacist NZ was revoked for creating, filling and sending a prescription out of state to her sister without authorization from a prescriber.
- Pharmacist DB was ordered a letter of reprimand; 2 extra hours of CE; and fined \$1K for dispensing the wrong strength of phenobarbital resulting in seizure activity in a canine. Pharmacy WG was fined an administrative fee of \$1500.
- Pharmacy Technician KR was revoked for diversion of controlled substances for self-administration.
- Physician CW's stipulated agreement was denied by the Board and asked to be heard in July. Two of CW's dispensing techs were revoked for dispensing without the physician's authority.

Other Activity:

- The usual Board business reports were given, including recent and future speaking engagements; reports on national meetings; and collaboration with other state agencies.
- The Board discussed a petition for regulatory interpretation regarding the authority to possess and administer dangerous drugs.
- The NABP "blueprint" inspection process was discussed and moved forward for Nevada inspections.

Public Hearing:

- A. **Amendment of Nevada Administrative Code Chapter 639 to add a new section thereto for the registration of veterinarians to dispense controlled substances or dangerous drugs.** Establishes the requirements for a licensed veterinarian to obtain a certificate of registration to dispense controlled substances or dangerous drugs; and revising the fees for a licensed veterinarian to dispense controlled substances or dangerous drugs. (LCB File No. R015-18)

- B. **Amendment of Nevada Administrative Code Chapter 639 to add a new section thereto authorizing the State Board of Pharmacy to issue an order for a hearing to show cause.** Enacts the requirements for the issuance of an order to appear at a hearing to show cause to a respondent to fails to comply with an order imposing discipline. (LCB File No. R014-18)